You just read:

CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors

News provided by

CSL Behring

Mar 23, 2018, 09:55 ET